47 results on '"Cecere, Fabiana Letizia"'
Search Results
2. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
3. The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world
4. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
5. Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials
6. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
7. BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients
8. Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy
9. Analysis of predictive factors of unforeseen nodal metastases in resected clinical stage I NSCLC
10. Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171).
11. Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)
12. A Real-World Systematic Analysis of Driver Mutations’ Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant Setting
13. AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with RET fusion–positive advanced/metastatic NSCLC.
14. Medical treatment of advanced non-small cell lung cancer in elderly patients: A review of the role of chemotherapy and targeted agents
15. Oncological Outcomes of Robotic Lobectomy and Radical Lymphadenectomy for Early-Stage Non-Small Cell Lung Cancer
16. Not enough can be enough: feasibility of the Idylla EGFR mutation test when reuse of stained tissue slides is the only option available.
17. Not enough can be enough: feasibility of the Idylla EGFR mutation test when reuse of stained tissue slides is the only option available
18. Outcome of crizotinib treatment in a young woman with heavily pretreated ROS1-positive lung cancer
19. A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer
20. Nodal Upstaging Evaluation After Robotic-Assisted Lobectomy for Early-Stage Non-small Cell Lung Cancer Compared to Video-Assisted Thoracic Surgery and Thoracotomy: A Retrospective Single Center Analysis
21. Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study
22. Gender Differences: Implications for Clinical Trials and Practice
23. Adjuvant Chemotherapy for Non-small Cell Lung Cancer
24. BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients
25. Predicting the Role of DNA Polymerase β Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy
26. Ovarian metastasis from malignant pleural mesothelioma
27. Thymic Epithelial Tumors as a Model of Networking: Development of a Synergistic Strategy for Clinical and Translational Research Purposes
28. First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
29. Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial)
30. Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study
31. Is Recurrent Venous Thromboembolism After Therapy Reduced by Low-Molecular-Weight Heparin Compared With Oral Anticoagulants?*
32. Lung cavitation in lung metastases of gastric and non-small-cell lung cancer patients treated with apatinib
33. Immunotherapy discontinuation and outcome: A multicenter real-life experience.
34. Not enough can be enough: feasibility of the Idylla EGFRmutation test when reuse of stained tissue slides is the only option available
35. Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)
36. Atezolizumab in a C o H ort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal Subtyp E s (CHANCE trial).
37. Updated outcomes of previously irradiated non-small-cell lung cancer (NSCLC) patients (pts) receiving programmed death 1 (PD-1) inhibitors.
38. Systemic effect of radiotherapy (RT) followed by programmed death 1 (PD-1) inhibitors in non-small-cell lung cancer (NSCLC).
39. Erratum to “Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813–819]”
40. IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.
41. Prolonged response to trabectedin in a heavily pretreated patient with metastatic endometrial carcinoma: A case report and literature review
42. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer
43. Customized first-line chemotherapy according to ERCC1 and RRM1 SNPs in advanced NSCLC patients: A phase II study.
44. Aromatase inhibitors in post-menopausal metastatic breast carcinoma
45. Severe rhabdomyolysis associated with pemetrexed-based chemotherapy
46. Should disease free survival (DFS) be used as a surrogate end-point in adjuvant chemotherapy trials for non-small-cell lung cancer (NSCLC)? Analysis of 7 randomized clinical trials (RCTS) exploring platinum-based chemotherapy
47. Prolonged response to trabectedin in a heavily pretreated patient with metastatic endometrial carcinoma: A case report and literature review.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.